Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome
Ross R. Jennens, Mark Andrew Rosenthal, Geoffrey John Lindeman et al. · Urologic Oncology Seminars and Original Investigations · 2004
Cited by 33 works. doi:10.1016/j.urolonc.2004.01.011
Authors
References
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
- SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
- von Hippel-Lindau disease
- Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
- von Hippel-Lindau disease: genetic, clinical, and imaging features.
- Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
- Flk-1 as a target for tumor growth inhibition.
- The natural history of hemangioblastomas of the central nervous system in patients with von Hippel—Lindau disease
- Receptor tyrosine kinases as targets for inhibition of angiogenesis
- Von Hippel-Lindau Syndrome